AI Analysis | Feedback

Here are 1-2 brief analogies to describe Cognition Therapeutics (CGTX):

• A clinical-stage Biogen, but laser-focused on small molecule treatments for Alzheimer's, Parkinson's, and related brain diseases.
• An emerging Eli Lilly, but specializing in therapies for neurodegenerative conditions and age-related eye diseases.

AI Analysis | Feedback

• CT1812: A lead sigma-2 receptor antagonist in clinical trials for Alzheimer's disease and Dementia with Lewy Bodies (DLB), and in preclinical development for dry age-related macular degeneration (AMD).
• CT2168: A therapeutic candidate being developed for synucleinopathies, including Dementia with Lewy Bodies (DLB) and Parkinson's disease.
• CT2074: A therapeutic candidate in development to treat dry age-related macular degeneration (AMD).

AI Analysis | Feedback

Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. As such, the company does not currently have approved products on the market and therefore does not have major customers in the traditional sense, selling products to other companies or individuals.

However, if its product candidates successfully complete clinical trials and receive regulatory approval, the company's ultimate end-users would be individuals suffering from the age-related degenerative diseases and disorders that its therapeutics are designed to treat. Based on its current pipeline, the primary categories of future customers would include:

• Individuals with Alzheimer's Disease: Patients suffering from mild-to-moderate or early-stage Alzheimer's disease, for whom CT1812 is being developed.
• Individuals with Synucleinopathies: Patients diagnosed with conditions such as Dementia with Lewy Bodies (DLB) or Parkinson's disease, targeted by CT1812 and CT2168.
• Individuals with Dry Age-Related Macular Degeneration (AMD): Patients experiencing dry AMD, for whom CT1812 and CT2074 are in development.

AI Analysis | Feedback

null

AI Analysis | Feedback

Lisa Ricciardi, Chief Executive Officer and President

Ms. Ricciardi has served as Cognition Therapeutics' Chief Executive Officer and President since March 2020 and as a member of its board of directors since March 2019. She possesses extensive experience in leadership roles at both startup and established biopharmaceutical companies. Prior to Cognition Therapeutics, she served as CEO of Suono Bio, a biotech company based on MIT technology, which she successfully led through a Series A fundraising round. Ms. Ricciardi also has a track record of selling companies she was involved with, having led deal teams for the sale of Foundation Medicine and Express Scripts, including brokering the $29 billion acquisition of Medco by Express Scripts. She also served as an entrepreneur in residence at Essex Woodlands Health Ventures, indicating experience with venture capital-backed life science companies.

John Doyle, Chief Financial Officer

Mr. Doyle joined Cognition Therapeutics as Chief Financial Officer in 2023. He is noted for his significant experience in raising capital, particularly in challenging market conditions, and in guiding companies through the stages leading to commercialization.

Anthony O. Caggiano, M.D., Ph.D., Chief Medical Officer, Head of R&D

Dr. Caggiano was appointed Chief Medical Officer and Head of R&D at Cognition Therapeutics in 2021. In this role, he is responsible for overseeing the ongoing and planned clinical trials of the company's lead product candidate, CT1812, for indications such as Alzheimer's disease, dry age-related macular degeneration (AMD), and dementia with Lewy bodies (DLB). He also guides the identification and optimization of preclinical candidates.

Mary Hamby, Ph.D., Vice President, Research

Dr. Hamby was promoted to Vice President of Research in 2021. She focuses on the discovery and development of disease-modifying therapeutics designed to treat age-related neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. Dr. Hamby joined Cognition Therapeutics in 2019 as director of biology and brings over 20 years of experience in neurodegenerative diseases and drug discovery from both academic and pharmaceutical/biotech settings.

Steven A. Weissman, Ph.D., Vice President and Head of Chemistry, Manufacturing, and Controls (CMC)

Dr. Weissman is responsible for the process development and manufacturing oversight of Cognition Therapeutics' lead candidate, zervimesine (CT1812). Before his tenure at Cognition Therapeutics, Dr. Weissman served as the director of chemical development at Lexicon Pharmaceuticals, where he was responsible for the clinical supply and eventual global commercial manufacturing of telotristat etiprate.

AI Analysis | Feedback

The key risks for Cognition Therapeutics (CGTX) are primarily associated with the inherent challenges of clinical-stage biopharmaceutical development:

1. Clinical Trial Success and Efficacy: As a clinical-stage company, Cognition Therapeutics' viability is heavily dependent on the successful outcome of its ongoing clinical trials. Its lead product candidate, CT1812, is in Phase II trials for Alzheimer's disease and dementia with Lewy bodies, which are critical and often high-failure stages of drug development. The failure of CT1812 or other product candidates to demonstrate sufficient efficacy and safety in clinical trials would significantly jeopardize the company's future.
2. Regulatory Approval: Even if clinical trials demonstrate positive results, there is no guarantee that regulatory authorities, such as the FDA, will approve the company's product candidates for commercialization. The process for obtaining regulatory approval for novel therapies in complex neurological diseases like Alzheimer's and DLB is stringent, lengthy, and subject to evolving standards and interpretations.
3. Funding and Capital Availability: Developing pharmaceutical products through multiple clinical phases and eventual commercialization is extremely costly. As a company without approved products generating revenue, Cognition Therapeutics is reliant on securing additional funding through equity offerings, debt financing, or strategic partnerships to continue its research and development efforts. A failure to obtain sufficient capital could delay or halt the development of its product pipeline.

AI Analysis | Feedback

• The recent FDA approvals of SYFOVRE (pegcetacoplan injection) from Apellis Pharmaceuticals and IZERVAY (avacincaptad pegol) from Iveric Bio for geographic atrophy secondary to dry age-related macular degeneration (AMD). These are the first approved treatments for a condition that Cognition Therapeutics is targeting with CT1812 (in preclinical trials) and CT2074 (in development), establishing a new standard of care and significantly raising the competitive bar for CGTX's preclinical programs in dry AMD.
• The recent FDA approval of Leqembi (lecanemab) from Eisai/Biogen and the anticipated approval of Donanemab from Eli Lilly, both disease-modifying monoclonal antibodies targeting amyloid-beta plaques in early Alzheimer's disease. These approvals introduce new treatments that establish a higher efficacy standard for early Alzheimer's disease, creating significant competition for Cognition Therapeutics' lead product candidate CT1812, which is in Phase II for mild-to-moderate Alzheimer's and has completed Phase I for early-stage Alzheimer's.

AI Analysis | Feedback

Cognition Therapeutics (CGTX) is focused on developing small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system and retina. The addressable markets for their main product candidates are substantial:

Alzheimer's Disease

The global Alzheimer's disease market is estimated to reach approximately USD 29.4 billion by 2035. Another report projects the Alzheimer's disease market across the 7 major markets (7MM: U.S., Germany, France, Italy, Spain, UK, and Japan) to grow from approximately USD 3,610 million in 2023 to USD 34,335 million by 2034. The U.S. market for Alzheimer's drugs was valued at USD 1.62 billion in 2022. In 2023, the United States accounted for approximately 54% of the total Alzheimer's disease market size in the 7MM.

Dementia with Lewy Bodies (DLB)

The global Lewy body dementia treatment market is expected to reach USD 13.32 billion by 2034. Other estimates indicate the global market size was valued at USD 5,972 million in 2024 and is projected to be worth USD 13,208 million by 2033. North America dominated the Lewy body dementia treatment market with a 41.3% revenue share in 2024. Within North America, the U.S. Lewy body dementia treatment market captured the largest share of 75% in 2024.

Parkinson's Disease

The global Parkinson's disease drugs market size is projected to grow from USD 7.75 billion in 2025 to USD 15.77 billion by 2034. The global Parkinson's disease therapeutics market was valued at USD 6.2 billion in 2024 and is projected to reach USD 13.3 billion by 2034. The U.S. Parkinson's disease market was approximately USD 1,883 million in 2023. The U.S. market for Parkinson's disease therapeutics was valued at USD 2.3 billion in 2024 and is projected to reach USD 2.45 billion by 2026.

Dry Age-related Macular Degeneration (AMD)

The global dry age-related macular degeneration (AMD) market, valued at USD 4.83 billion in 2023, is expected to reach USD 10.57 billion by the end of 2032. Another source reports the market was valued at USD 5.27 billion in 2024 and is expected to reach USD 10.58 billion by 2032. For the U.S. market, the total Dry Age-related Macular Degeneration market size was estimated to be approximately USD 800 million in 2023. North America dominated the Dry Age-Related Macular Degeneration market in 2024 with a 46.3% share.

AI Analysis | Feedback

For Cognition Therapeutics (CGTX), a clinical-stage biopharmaceutical company, expected drivers of future revenue growth over the next 2-3 years are intrinsically tied to the advancement and potential commercialization of its lead drug candidate, zervimesine (CT1812), and the strategic partnerships it may form. While direct product sales are likely beyond this immediate timeframe, key milestones and collaborations are expected to generate revenue.

1. Advancement and Positive Data from CT1812 in Alzheimer's Disease (AD) Program: Cognition Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on a registrational path for zervimesine in mild-to-moderate Alzheimer's disease and has presented plans for Phase 3 studies. The ongoing Phase 2 START study for early AD is actively enrolling patients. Positive outcomes from the START study, successful initiation, and significant progression of Phase 3 trials would be critical catalysts. Such progress could lead to substantial milestone payments from existing or new partnerships, or enhance the company's valuation for future non-dilutive funding opportunities, well before commercialization.
2. Progression of CT1812 in Dementia with Lewy Bodies (DLB) Program: Following positive Phase 2 SHIMMER trial data and receipt of final FDA Type C meeting minutes, Cognition Therapeutics plans to advance zervimesine toward a registrational program for DLB psychosis. The initiation of an Expanded Access Program (EAP) for DLB, substantially funded by a philanthropic donation, also signals promising results and patient interest. Continued successful advancement through clinical development and toward regulatory approval in this indication would generate similar revenue-driving opportunities through partnerships and milestone payments.
3. Securing Strategic Partnerships and Non-Dilutive Funding: As a clinical-stage company, Cognition Therapeutics actively seeks and relies on strategic partnerships for late-stage development and potential commercialization of its drug candidates. Tier 1 strategic partners are a primary focus for securing non-dilutive funding. Such collaborations typically involve upfront payments upon signing, milestone payments contingent on achieving specific clinical or regulatory goals, and future royalties on sales. Additionally, continued receipt of government grants, such as those from the National Institute of Aging (NIA), which have significantly supported their AD and DLB trials, will continue to contribute to revenue.

AI Analysis | Feedback

Share Issuance

• Cognition Therapeutics completed an Initial Public Offering (IPO) in October 2021, generating approximately $52 million in gross proceeds by issuing around 5.5 million shares, including an overallotment.
• In September 2025, the company closed a $30 million registered direct offering, selling 14.7 million shares of common stock at $2.05 per share to two new institutional investors.
• In March 2024, Cognition Therapeutics conducted a public offering of 6,571,428 shares of common stock at $1.75 per share, expecting to receive net proceeds of approximately $10.4 million.

Inbound Investments

• The company has secured over $170 million in non-dilutive grant funding from the National Institutes of Health (NIH) and National Institute on Aging (NIA) to support its research and clinical programs.
• Notable grants include an $81 million grant for the START Alzheimer's disease trial, $30 million for the SHINE AD trial, and $30 million for the SHIMMER DLB trial.
• As of the third quarter of 2025, the company reported $36.3 million in remaining obligated NIA grant funds.

Capital Expenditures

• Cognition Therapeutics' annual capital expenditure showed a decreasing trend with a 5-year growth rate of -51.2%.
• Capital expenditures were reported as $1,000 in Q3 2024.
• Research and development expenses, a primary focus for the company, were $3.8 million for the quarter ended September 30, 2025, a decrease from $11.4 million in the comparable period of 2024, largely due to the completion of the SHINE and SHIMMER clinical trials.